AbbVie Exec Says Apogee Fits 'Very Nicely' With Its Business Development Approach; Says Existing Portfolio Provides 'Clear Line Of Sight' To Very Strong Growth Well Into Next Decade
- conference call
Share
Why It Matters
AbbVie bought Apogee and thinks it fits their company plan well. The leader sees their medicines and new deals leading to strong growth for many years ahead.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.